Hsbc Holdings PLC Invests $216.43 Million in Stryker Corporation $SYK

Hsbc Holdings PLC purchased a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 688,707 shares of the medical technology company’s stock, valued at approximately $216,432,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Brighton Jones LLC raised its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new position in Stryker during the second quarter valued at $205,000. Marshall Wace LLP increased its position in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in Stryker in the second quarter worth $219,000. Finally, HUB Investment Partners LLC bought a new stake in shares of Stryker in the second quarter valued at $253,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SYK has been the topic of a number of research reports. Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Raymond James Financial set a $370.00 target price on shares of Stryker in a research report on Friday, July 31st. Needham & Company LLC reduced their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Finally, Citigroup reaffirmed a “buy” rating on shares of Stryker in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Up 1.0%

Shares of NYSE:SYK opened at $331.06 on Wednesday. The firm has a fifty day moving average price of $327.80 and a two-hundred day moving average price of $331.95. The company has a market cap of $126.98 billion, a price-to-earnings ratio of 34.31, a PEG ratio of 2.09 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 36.48%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 355,370 shares of company stock valued at $119,447,201 over the last 90 days. 4.60% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.